DeepMed Research

Yonsei University

🇰🇷South Korea

Country: 🇰🇷South Korea

Ownership: Private

Established: 1885-01-01

Employees: 5K

Market Cap: -

Website: http://www.yonsei.ac.kr

Clinical Trials

The Effects of Sufentanil vs. Remifentanil in Total Intravenous Anesthesia With Remimazolam on Postoperative Pain

Not Applicable

Recruiting

Conditions: Stomach Neoplasms

Interventions: Drug: sufentanil-remimazolam group
Drug: remifentanil-remimazolam group

First Posted Date: 2023-03-27

Last Posted Date: 2023-03-27

Lead Sponsor: Yonsei University

Target Recruit Count: 66

Registration Number: NCT05785234

Locations: 🇰🇷
Department of Anesthesiology and Pain Medicine, Anesthesia and Pain Research Institute, Yonsei University College of Medicine, Seoul, Korea, Republic of

Lazertinib+Pemetrexed/Carboplatin in Patients With EGFR Sensitizing Mutation Positive Recurrent or Metastatic Non-Small Cell Lung Cancer Failed to Prior Lazertinib

Phase 2

Not yet recruiting

Conditions: Non-small Cell Lung Cancer

Interventions: Drug: Lazertinib/Pemetrexed/Carboplatin

First Posted Date: 2023-03-27

Last Posted Date: 2023-03-27

Lead Sponsor: Yonsei University

Target Recruit Count: 87

Registration Number: NCT05786430

Locations: 🇰🇷
Yonsei University Health System, Severance Hospital, Seoul, Korea, Republic of

Effect of High-intensity Statin With Ezetimibe COmbination theRapy Versus High-intensity sTatin Monotherapy After Percutaneous Coronary Intervention With Drug-eluting Stents; the ESCORT Trial

Not Applicable

Recruiting

Conditions: Coronary Artery Disease Requiring Coronary Revascularization With Newer Generation DES Implantation

Interventions: Drug: ezetimibe/high-intensity statin combination therapy (ezetimibe 10mg plus atoravastatin 40mg)
Drug: high-intensity statin monotherapy (atoravastatin 40mg)

First Posted Date: 2023-03-24

Last Posted Date: 2024-03-15

Lead Sponsor: Yonsei University

Target Recruit Count: 4310

Registration Number: NCT05782777

Locations: 🇰🇷
Yonsei University Health System, Severance Hospital, Seoul, Korea, Republic of

Safety and Efficacy of Distal Radial Approach (SAFE-BOX)

Recruiting

Conditions: Efficacy
Safety

First Posted Date: 2023-03-20

Last Posted Date: 2024-03-15

Lead Sponsor: Yonsei University

Target Recruit Count: 3600

Registration Number: NCT05776550

Locations: 🇰🇷
Yongcheol Kim, Yongin, Gyeonggi-do, Korea, Republic of

The Role of Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma in Immuno-oncology Era: SEVURO-CN Trial

Not Applicable

Recruiting

Conditions: Synchronous Neoplasm
Kidney Cancer
Clear Cell Renal Cell Carcinoma Metastatic

Interventions: Procedure: Cytoreductive nephrectomy±metastasectomy
Other: Human-derived materials sampling

First Posted Date: 2023-03-03

Last Posted Date: 2023-06-22

Lead Sponsor: Yonsei University

Target Recruit Count: 40

Registration Number: NCT05753839

Locations: 🇰🇷
Yonsei University Health System, Severance Hospital, Seoul, Korea, Republic of
🇰🇷
Yongin Severance Hospital, Yongin-si, Korea, Republic of
🇰🇷
Gangnam Severance Hospital, Seoul, Korea, Republic of

First-line Trastuzumab, Gemcitabine, Cisplatin and Nivolumab in Advanced HER2- Positive Biliary Tract Cancer: a Multicenter, Open-label, Single-arm Phase Ib/II Trial (HERBOT)

Phase 1

Recruiting

Conditions: HER2 Positive Advanced/Metastatic/Nonresectable Biliary Tract Cancer

Interventions: Drug: Trastuzumab+Nivolumab+Gemcitabine+Cisplatin

First Posted Date: 2023-03-01

Last Posted Date: 2025-02-05

Lead Sponsor: Yonsei University

Target Recruit Count: 44

Registration Number: NCT05749900

Locations: 🇰🇷
Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of

Portal Hypertension Using Magnetic Resonance Elastography

Completed

Conditions: Magnetic Resonance Imaging
Portal Hypertension

First Posted Date: 2023-03-01

Last Posted Date: 2023-03-01

Lead Sponsor: Yonsei University

Target Recruit Count: 47

Registration Number: NCT05749198

Locations: 🇰🇷
Wonju Severance Christian Hospital, Wŏnju, Gangwon, Korea, Republic of

Effect of Mirabegron on Bladder Compliance

Not Applicable

Active, not recruiting

Conditions: Patients With Low Bladder Compliance of 20ml/H2O or Less Despite Taking Anticholinergics

Interventions: Drug: Mirabegron (beta3-adrenoceptor agonist), Anticholinergics

First Posted Date: 2023-02-27

Last Posted Date: 2023-02-27

Lead Sponsor: Yonsei University

Target Recruit Count: 15

Registration Number: NCT05745584

Locations: 🇰🇷
Yonsei University Health System, Severance Hospital, Seoul, Korea, Republic of

Cancer Stem Cell Specific Aptamer's Ability to Detect Blood Circulating Cancer Stem Cells and Its Role as a Predictor of Prognosis in Pancreatic Cancer

Completed

Conditions: Pancreatic Neoplasm

First Posted Date: 2023-02-27

Last Posted Date: 2023-02-27

Lead Sponsor: Yonsei University

Target Recruit Count: 40

Registration Number: NCT05745415

Locations: 🇰🇷
Yonsei University Health System, Severance Hospital, Seoul, Korea, Republic of

Comparison of Remimazolam and Midazolam for Preventing Intraoperative Nausea and Vomiting During Cesarean Section Under Spinal Anesthesia

Not Applicable

Completed

Conditions: Cesarean Section
Spinal Anesthesia
Pregnancy

Interventions: Drug: Remimazolam besylate
Drug: Midazolam

First Posted Date: 2023-02-21

Last Posted Date: 2024-02-06

Lead Sponsor: Yonsei University

Target Recruit Count: 80

Registration Number: NCT05736341

Locations: 🇰🇷
Yonsei University Health System, Severance Hospital, Seoul, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy